Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
Company to discuss clinical progress of Trappsol® Cyclo™ development program for the treatment of Niemann-Pick Disease Type C (NPC) GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage...
Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
Global clinical protocol agreed upon by US Food and Drug Administration (FDA) and European MedicinesAgency (EMA) GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...
Cyclo Therapeutics Announces Launch of New Website
- Company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases- Pivotal Phase 3 study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C (NPC) on track to commence site...
Cyclo Therapeutics Announces Inclusion in the Russell 2000® Index
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from...
Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference
Live video webcast presentation with members of the Company's executive leadership team on Thursday, June 17th at 12:30 PM ETGAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company...
Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimer’s Disease Panel
- Panel discussion around innovating Alzheimer's Disease ("AD") drug development on Wednesday, May 26th 11:00 AM ETGAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
- Pivotal Phase 3 study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C (NPC) on track to commence enrollment and dosing in Q2 2021- Company advancing Alzheimer's Disease Phase 2 asset towards investigational new drug application (IND) filing...
Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy
Ms. Gorski brings more than two decades of communications and patient advocacy experience serving rare disease communitiesFormerly led global communications and patient advocacy strategies for lysosomal storage disorders at Sanofi Genzyme GAINESVILLE, Fla. - Cyclo...
Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
Patient enrollment on track to commence in Q2 2021Global clinical protocol agreed with US Food and Drug Administration (FDA) and European MedicinesAgency (EMA)Dual primary objectives agreed; FDA 4-Domain Niemann-Pick disease Type C-Severity Scale (4D-NPC-SS) and EMA...